Immunogenicity Assay Development, Validation & Transfer in a Vaccine Candidate Clinical Trial
A large global pharmaceutical company, with a promising new vaccine candidate, partnered with Viracor Eurofins to perform immunogenicity testing as part of their clinical trial development. Several specific areas of expertise were called upon to enable the Viracor team to deliver multiple precise, robust and sensitive assays to meet the sponsor's needs.
Validation and Transfer of Biodistribution and Viral Shedding Assays In Development of An Oncolytic Virus Immunotherapy Candidate
Several new immunotherapy technologies, such as cancer vaccines, adoptive cell (CAR T-cell), and checkpoint inhibitor therapies, have emerged as promising approaches to treating cancer patients. Oncolytic virus therapies in particular, combine selective tumor cell killing and induction of anti-cancer immune reactions. Among the most significant safety and efficacy concerns in development of this new class of drugs are neutralization and clearance of virus particles. Check out this case study to learn about methods used to help characterize the biodistribution and transmissibility of an oncolytic virus candidate in a clinical trial.